

Clone ID	Ff-I14s04-AB II-KO-24	Product	Human iPS cells	
Source	Peripheral Blood, Human	Race	Japanese	
Passage No.	32	Gender	Male	
Label Name	21B79	Manufacture	Feb. 15 th , 2021	
		Dates		
Culture medium	StemFit AK03N	Substrate	iMatrix-511MG	
Culture Method	Feeder-free (**2)			
Genome-editing	CRISPR-Cas9 (**2)			
techniques				
Use and Provision	Please check our web site ;			
of this cell stock	https://www.cira-foundation.or.jp/e/project/index.html			

• Ff-I14s04-AB II-KO-24(QHJI; iPS cells expressing the highest HLA in Japan *1)

(%1) **Reference;** Okita, *et. al.*, Nat Methods. 2011 8(5): 409-412

(%2) **Reference**; Huaigeng Xu, et al. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility. Cell Stem Cell. 2019 Apr 4;24(4):566-578.

For Research Use Only

Test Result

Test	Method	Result	
Sterility	BacT/ALERT	Negative	
Mycoplasma	PCR	Negative	
Endotoxin	LAL	< 0.017 EU/mL	
Morphology Microscope		Consistent with human ES cells	
STR genotyping PCR		Consistent with the donor cells	
Karyotype	G-banding	46,XY[20]	
CNV ^(*)	WGS, SNP	No de novo CNVs (>1kbp) were found in COSMIC Cancer Gene Census (ver.88) and Shibata list ^(\times4) .	
SNV/Indel ^(#3)	WGS	No de-novo non-synonymous SNVs/Indels were found in COSMIC Cancer Gene Census (ver.88) and Shibata list ^(※4) .	
	Sanger Sequencing	Detected of edits	
Gene editing confirmation	Flow cytometry	HLA-A(-) = 99.92 % HLA-C(+) = 100 %	
Cardiac differentiation Reference: "Funakoshi et al., 2016, Sci Rep."		TnT(+) = 80.11 %	
Undifferentiated markers	Flow cytometry	TRA-1-60(+): 89.6 %	
Thawed postnatal cellsCounting the number of the cells $($ *5 $)$		1.92 × 10 ⁵ cells (Survival rate ; 95.2 %)	




Number of proliferating cells	Counting the number of the cells after culturing	5.92 $\times 10^5$ cells (Number of seeded cells :
after thawing		0.68×10^5 cells)
arter thawing	for 4 days ^(%5) .	

(%3) CNV; Copy Number Variation , SNV/Indel; Single nucleotide variants /Insertion Deletion

(%4) The PMDA Science Board "Current Perspective on Evaluation of Tumorigenicity of Cellular- and Tissue-based Products Derived from induced Pluripotent Stem Cells (iPSCs) and iPSCs as Their Starting Materials" (Cellularand Tissue-based Products Subcommittee, 20 August 2013)

(%5) NucleoCounter® NC200

∎lmage



Please contact us if you have any questions.

(ips-request@cira-foundation.or.jp)



Reprint or reproduction of this page without permission is prohibited.